Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

Date: July 31, 2014
Pages: 143
Price:
US$ 4,995.00
License [?]:
Publisher: GBI Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N33E0AF720CEN
Leaflet:

Download PDF Leaflet

Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

Summary

GBI Research, a leading business intelligence provider, has released its latest research report, “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market”. The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment.

The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma. Common genetic and molecular aberrations within these histologies are being extensively researched and targeted by novel therapeutics and so the treatment algorithm between histological subtypes is forecast to become more differentiated over the forecast period. Most notably, patients with squamous cell carcinoma are set to benefit from crucial first- and second-line therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the past decade. Non-squamous patients, on the other hand, have several successful histology-specific therapies, such as Alimta (pemetrexed), and mutation-specific therapies, such as Tarceva (erlotinib), that are already marketed. New second-line entrants will create a crowded and competitive environment. The generic erosion of market leaders Alimta and Tarceva late in the forecast period will make this a tough environment for new products that have shown only minor improvements in safety or efficacy.

Despite the potential of targeted therapies and the identification of several promising molecular targets, the development of these products remains in the early-stage pipeline. Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations are likely to remain the only identified intracellular molecular aberrations targeted by marketed products, both of which are mainly found in adenocarcinoma tumors. Instead, the late-stage pipeline is primarily occupied by immunotherapies, which still offer a greater degree of specificity than chemotherapies; however, they initiate tumor destruction via the immune system. Necitumumab, Yervoy and nivolumab are all Phase III immunotherapies expected to reach the market in the forecast period, each with a different target.

Resistance to targeted therapies is a significant issue in the NSCLC market as the onset of acquired resistance to therapies such as Tarceva or Xalkori (crizotinib) has greatly reduced their potential. Despite the limited late-stage pipeline activity with new molecular targets, there are new drugs targeting EGFR and ALK that may combat resistance, thereby increasing the time frame in which patients are treatable with targeted therapy. Gilotrif (afatinib) is a recently launched EGFR inhibitor with a novel mechanism of action that may delay the onset of resistance, and Zykadia (LDK378) is an ALK inhibitor in the late-stage pipeline that is set to treat Xalkori-resistant patients.

Scope

The report assesses the current NSCLC market and predicts market trends to 2020, analyzing key drivers and barriers.The areas covered include
  • A disease introduction, which defines the disease and looks at symptoms, diagnosis and treatment
  • Analysis of the NSCLC marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of NSCLC treatment
  • Detailed analysis of the NSCLC pipeline, covering among other parameters, drug distribution by Phase, molecule type and mechanism of action. The NSCLC clinical trial landscape is analyzed with particular emphasis on failure rates across different trial Phases, as well as the trends in clinical trial size, duration and primary endpoint. This section also includes profiles and single product forecasts for the most promising pipeline drugs.
  • An epidemiological forecast of the major NSCLC markets, in which projected values include total and treated populations
  • An in-depth forecasting model for the NSCLC market, which considers the current marketed therapies in addition to the potential entry of new products to the market. The model comprises a projected outcome with high and low variance results depending on the potential performance of pipeline therapies.
  • Analysis of strategic consolidations within the NSCLC indication, including co-development and licensing agreements
  • An overview of the drivers of and barriers to the NSCLC market
Reasons to buy

The report will enable clients to develop a strong understanding of NSCLC as a disease and as a market. The current therapeutic needs and future market trends will highlight opportunities and the Scope of competition between NSCLC therapeutics. Primarily, the report will allow clients to
  • Understand the NSCLC pipeline and the clinical needs that it is addressing, particularly the ways in which histology affects treatment options and where in the treatment algorithm new products will be positioned, as well as where unmet needs remain
  • Develop their knowledge of key products that may enter the market before 2020. Detailed profiles of these products are provided, with a focus on their clinical trial performance, as well as how they can be incorporated into the NSCLC treatment plan and what competition they face.
  • Assess the risk associated with NSCLC product development profiled by molecule type and mechanism of action and compared with both industry and therapy-area averages. In addition, data analyses offer a more detailed understanding of the trends in both trial size and duration for specific mechanisms of action or molecule types. The primary endpoint analysis infers trends in trial design within the therapy area, as well as the endpoints that are the best indicators of success.
  • Identify patterns of growth in the NSCLC market over the forecast period and understand the underlying causes, as well as observing the contributions made by each major market and/or late-stage pipeline drug to this growth.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Disease Introduction
2.2 Epidemiology
2.3 Etiology and Pathophysiology
  2.3.1 Adenocarcinoma
  2.3.2 Squamous Cell Carcinoma
  2.3.3 Large Cell Carcinoma
  2.3.4 Immunotherapy
2.4 Symptoms
2.5 Diagnosis
2.6 Prognosis
2.7 Treatment
  2.7.1 Treatment Algorithm
  2.7.2 First-Line Treatment
  2.7.3 Maintenance Therapy
  2.7.4 Second-Line Therapy
  2.7.5 Third-Line Therapy
  2.7.6 Adjuvant Therapy

3 MARKETED PRODUCTS

3.1 Overview
3.2 Chemotherapies – Various
  3.2.1 Cisplatin
  3.2.2 Carboplatin
  3.2.3 Vinorelbine
  3.2.4 Paclitaxel
  3.2.5 Docetaxel
  3.2.6 Gemcitabine
3.3 Alimta – Eli Lilly
3.4 Abraxane – Celgene Corporation
3.5 Tarceva – Roche
3.6 Iressa – AstraZeneca
3.7 Gilotrif – Boehringer Ingelheim
3.8 Xalkori – Pfizer
3.9 Avastin (bevacizumab) – Roche
3.10 Marketed Products Heatmap
3.11 Conclusion

4 NSCLC PIPELINE

4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
  4.3.1 Failure Rate
  4.3.2 Clinical Trial Duration
  4.3.3 Clinical Trial Size
  4.3.4 Clinical Trial Primary Endpoints
4.4 Late-Stage Pipeline Product Profiles
  4.4.1 Custirsen – Teva Pharmaceutical Industries
  4.4.2 Halaven – Eisai
  4.4.3 Dacomitinib – Pfizer
  4.4.4 Vargatef – Boehringer Ingelheim
  4.4.5 Necitumumab – Eli Lilly
  4.4.6 Ganetespib – Synta Pharmaceuticals
  4.4.7 Zykadia– Novartis
  4.4.8 Yervoy – Bristol Myers Squibb
  4.4.9 Nivolumab – Ono Pharmaceuticals/Bristol-Myers Squibb
  4.4.10 MK-3475 – Merck
  4.4.11 RG7446 – Roche
  4.4.12 Cyramza– Eli Lilly
  4.4.13 Tavocept – BioNumerik Pharmaceuticals
  4.4.14 Tecemotide – Merck Serono
  4.4.15 Tertomotide – KAEL-GemVax
  4.4.16 Lucanix – NovaRx Corporation
  4.4.17 Bevacizumab Biosimilar – Various
4.5 Safety and Efficacy Heatmap
4.6 Conclusion
  4.6.1 Product Competitiveness Framework
  4.6.2 Future Treatment Algorithm

5 MARKET FORECAST

5.1 Geographical Markets
  5.1.1 Global Markets
  5.1.2 North America
  5.1.3 Top Five EU Countries
  5.1.4 Japan
5.2 Drivers and Barriers
  5.2.1 Drivers
  5.2.2 Barriers

6 STRATEGIC CONSOLIDATIONS

6.1 Major Co-Development deals
  6.1.1 Merck Enters into Co-Development Agreement with Endocyte
  6.1.2 Exelixis Enters into a Co-Development Agreement with Genentech
  6.1.3 CancerVax Enters into an Agreement with CIMAB and YM Biosciences
  6.1.4 SFJ Pharma Enters into Co-Development Agreement with Pfizer for Dacomitinib
  6.1.5 OxOnc Development Enters into Co-Development Agreement with Pfizer for Crizotinib
6.2 Major Licensing Deals
  6.2.1 Merck Serono Enters into Licensing Agreement with Ono Pharma
  6.2.2 Astellas Pharma Enters into Licensing Agreement with Aveo Pharma
  6.2.3 Clovis Oncology Enters into a Licensing Agreement with Avila Therapeutics
  6.2.4 Novartis Enters into Licensing Agreement with Antisoma
  6.2.5 Cell Therapeutics Enters into Licensing Agreement with Novartis

7 APPENDIX

7.1 References
7.2 Market Definition
7.3 Abbreviations
  7.3.1 Research Methodology
  7.3.2 Secondary Research
  7.3.3 Marketed Product Profiles
  7.3.4 Late-Stage Pipeline Candidates
  7.3.5 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
  7.3.6 Product Competitiveness Framework
  7.3.7 Pipeline Analysis
  7.3.8 Forecasting Model
  7.3.9 Deals Data Analysis
7.4 Contact Us
7.5 Disclaimer

LIST OF TABLES

Table 1: Non-Small Cell Lung Cancer Market, Global, Tumor Node Metastasis Classification, 2014
Table 2: Non-Small Cell Lung Cancer Market, Global, Eastern Co-operative Oncology Group Criteria, 2014
Table 3: Non-Small Cell Lung Cancer Market, Global, Treatment Options, 2014
Table 4: Non-Small Cell Lung Cancer Market, Global, Stage IIIB–IV Treatment Options, 2014
Table 5: Non-Small Cell Lung Cancer Market, Global, Chemotherapy Treatment, 2014
Table 6: Non-Small Cell Lung Cancer Market, Global, Chemotherapy Treatment by Regimen, 2014
Table 7: Non-Small Cell Lung Cancer Market, Global, Pipeline, Preclinical, 2014
Table 8: Non-Small Cell Lung Cancer Market, Global, Pipeline, Phase I, 2014
Table 9: Non-Small Cell Lung Cancer Market, Global, Pipeline, Phase II, 2014
Table 10: Non-Small Cell Lung Cancer Market, Global, Pipeline, Phase III, 2014
Table 11: Non-Small Cell Lung Cancer Market, Global, Pipeline, Pre-registration, 2014
Table 12: Non-Small Cell Lung Cancer Market, Global, Pipeline, Undisclosed, 2014
Table 13: Non-Small Cell Lung Cancer Market, Global, Market Forecast, 2013-2020
Table 14: Non-Small Cell Lung Cancer Market, US, Market Forecast, 2013-2020
Table 15: Non-Small Cell Lung Cancer Market, Canada, Market Forecast, 2013-2020
Table 16: Non-Small Cell Lung Cancer Market, UK, Market Forecast, 2013-2020
Table 17: Non-Small Cell Lung Cancer Market, France, Market Forecast, 2013-2020
Table 18: Non-Small Cell Lung Cancer Market, Germany, Market Forecast, 2013-2020
Table 19: Non-Small Cell Lung Cancer Market, Italy, Market Forecast, 2013-2020
Table 20: Non-Small Cell Lung Cancer Market, Spain, Market Forecast, 2013-2020
Table 21: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2013-2020

LIST OF FIGURES

Figure 1: Non-Small Cell Lung Cancer Market, Global, Molecular Characteristic Frequency (%), 2014
Figure 2: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Late-Stage Treatment Algorithm, 2014
Figure 3: Non-Small Cell Lung Cancer Market, Global, Squamous Late-Stage Treatment Algorithm, 2014
Figure 4: NSCLC, Global, Marketed Products Heatmap, 2013
Figure 5: Non-Small Cell Lung Cancer, Global, Pipeline Summary, 2014
Figure 6: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Overview, 2014
Figure 7: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Breakdown, 2014
Figure 8: Non-Small Cell Lung Cancer, Global, Clinical Trial Attrition Rates (%), 2006–2014
Figure 9: Non-Small Cell Lung Cancer, Global, Clinical Trial Mechanism of Action Failure Rates by Phase (%), 2006–2014
Figure 10: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration (months), 2006–2013
Figure 11: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Molecule Type (months), 2006–2013
Figure 12: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Mechanism of Action (months), 2006–2013
Figure 13: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product (participants), 2006–2013
Figure 14: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2013
Figure 15: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Mechanism of Action (months), 2006–2013
Figure 16: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoints, 2006–2013
Figure 17: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoint Combinations by Phase (%), 2006–2013
Figure 18: Non-Small Cell Lung Cancer Pipeline, Global, Custirsen Annual Sales ($m), 2018–2020
Figure 19: Non-Small Cell Lung Cancer Pipeline, Global, Halaven Annual Sales ($m), 2016–2020
Figure 20: Non-Small Cell Lung Cancer Pipeline, Global, Dacomitinib Annual Sales ($m), 2014–2020
Figure 21: Non-Small Cell Lung Cancer Pipeline, Global, Vargatef Annual Sales ($m), 2015–2020
Figure 22: Non-Small Cell Lung Cancer Pipeline, Global, Necitumumab Annual Sales ($m), 2015–2020
Figure 23: Non-Small Cell Lung Cancer Pipeline, Global, Ganetespib Annual Sales ($m), 2016–2020
Figure 24: Non-Small Cell Lung Cancer Pipeline, Global, Zykadia Annual Sales ($m), 2014–2020
Figure 25: Non-Small Cell Lung Cancer Pipeline, Global, Yervoy Annual Sales ($m), 2015–2020
Figure 26: Non-Small Cell Lung Cancer Pipeline, Global, Nivolumab Annual Sales ($m), 2015–2020
Figure 27: Non-Small Cell Lung Cancer Pipeline, Global, Cyramza Annual Sales ($m), 2015–2020
Figure 28: Non-Small Cell Lung Cancer Pipeline, Global, Tavocept Annual Sales ($m), 2017–2020
Figure 29: Non-Small Cell Lung Cancer Pipeline, Global, Tertomotide Annual Sales ($m), 2017–2020
Figure 30: Non-Small Cell Lung Cancer Pipeline, Global, Lucanix Annual Sales ($m), 2016–2020
Figure 31: Non-Small Cell Lung Cancer , Global, Safety and Efficacy Heatmap, 2013
Figure 32: Non-Small Cell Lung Cancer , Global, Marketed Products Heatmap, 2013
Figure 33: Non-Small Cell Lung Cancer Market, Global, Product Competitiveness Framework, 2014
Figure 34: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Future Treatment Algorithm 2020
Figure 35: Non-Small Cell Lung Cancer Market, Global, Squamous Future Treatment Algorithm
Figure 36: Non-Small Cell Lung Cancer Market, Global, Treatment Patterns (‘000), 2013–2020
Figure 37: Non-Small Cell Lung Cancer Market, Global, Market Size ($bn), 2013–2020
Figure 38: Non-Small Cell Lung Cancer Market, North America, Treatment Usage Patterns (‘000), 2013–2020
Figure 39: Non-Small Cell Lung Cancer Market, North America, Annual Cost of Treatment ($), 2013–2020
Figure 40: Non-Small Cell Lung Cancer Market, North America, Market Size, 2013–2020
Figure 41: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Treatment Patterns (‘000), 2013–2020
Figure 42: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013–2020
Figure 43: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Market Size ($m), 2013–2020
Figure 44: Non-Small Cell Lung Cancer Market, Japan, Treatment Usage Patterns (‘000), 2013–2020
Figure 45: Non-Small Cell Lung Cancer Market, Japan, Annual Cost of Treatment ($), 2013–2020
Figure 46: Non-Small Cell Lung Cancer Market, Japan, Market Size ($bn), 2013–2020
Figure 47: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Region, 2006–2014
Figure 48: Non-Small Cell Lung Cancer, Global, Number of Co-Development Deals, 2006–2014
Figure 49: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Phase, 2006–2014
Figure 50: Non-Small Cell Lung Cancer, Global, Licensing Deals by Region, 2006–2014
Figure 51: Non-Small Cell Lung Cancer, Global, Number of Licensing Deals, 2006–2014
Figure 52: Non-Small Cell Lung Cancer, Global, Licensing Deals by Phase, 2006–2014

Ask Your Question

Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: